Reason for request
Reassessment
Clinical Benefit
| Insufficient |
The Committee deems that the clinical benefit of BLENREP (belantamab mafodotin) 100 mg, powder for solution for dilution for infusion, is insufficient in the MA indication to justify public funding.
|
Clinical Added Value
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
m2udyxfUefG2J2tZ